麻风病治疗中的药物递送系统：朝着根除目标迈进？

Chaves Luíse L, Patriota Yuri, Soares-Sobrinho José L, Vieira Alexandre C C, Lima Sofia A Costa, Reis Salette

Laboratório Associado para a Química Verde, Rede de Química e Tecnologia, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, 4050-313 Porto, Portugal.

Núcleo de Controle de Qualidade de Medicamentos e Correlatos, Universidade Federal de Pernambuco, Recife 50740-521, Brazil.

Pharmaceutics. 2020 Dec 11;12(12):1202. doi: 10.3390/pharmaceutics12121202.

Leprosy disease remains an important public health issue as it is still endemic in several countries. , the causative agent of leprosy, presents tropism for cells of the reticuloendothelial and peripheral nervous system. Current multidrug therapy consists of clofazimine, dapsone and rifampicin. Despite significant improvements in leprosy treatment, in most programs, successful completion of the therapy is still sub-optimal. Drug resistance has emerged in some countries. This review discusses the status of leprosy disease worldwide, providing information regarding infectious agents, clinical manifestations, diagnosis, actual treatment and future perspectives and strategies on targets for an efficient targeted delivery therapy.

麻风病仍然是一个重要的公共卫生问题，因为在一些国家它仍然是地方病。麻风病的病原体对网状内皮系统和周围神经系统的细胞具有嗜性。目前的多药疗法包括氯法齐明、氨苯砜和利福平。尽管麻风病治疗有了显著改善，但在大多数项目中，治疗的成功完成率仍不理想。一些国家已经出现了耐药性。本综述讨论了全球麻风病的状况，提供了有关传染源、临床表现、诊断、实际治疗以及有效靶向递送治疗靶点的未来前景和策略的信息。